Reference health
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
68/68 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
23 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 68 checked references that resolve
resolves10.1159/000235503
Humoral Transplantation Antibodies Play a Role in Protracted Rejection of Murine Renal Allografts
resolves10.1016/j.humimm.2005.01.021
Humoral Theory of Transplantation: Mechanism, Prevention, and Treatment
resolves10.1172/JCI110005
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.
resolves10.1002/j.1460-2075.1988.tb02867.x
Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains.
resolves10.1182/blood.V84.8.2457.2457
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
resolves10.1182/blood.V83.2.435.435
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
resolves10.1023/A:1008265313133
Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma
resolves10.1097/01.TP.0000112934.12622.2B
Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1
resolves10.1016/j.rdc.2004.01.006
B lymphocyte depletion therapy with rituximab in rheumatoid arthritis
resolves10.1177/0091270005277075
Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial
resolves10.1093/annonc/mdi320
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
resolves10.1016/j.transproceed.2004.12.066
New Crossmatch Technique Eliminates Interference by Humanized and Chimeric Monoclonal Antibodies
resolves10.1016/j.jim.2005.03.001
Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing
resolves10.1002/art.10764
The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
resolves10.1200/JCO.2003.05.013
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
resolves10.4049/jimmunol.174.2.817
Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
resolves10.1007/s00281-004-0190-2
B cell superantigens: a microbe?s answer to innate-like B cells and natural antibodies
resolves10.4049/jimmunol.134.6.3656
Studies on the induction of tolerance to alloantigens. I. The abrogation of potentials for delayed-type-hypersensitivity response to alloantigens by portal venous inoculation with allogeneic cells.
resolves10.1016/S0966-3274(03)00059-5
Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys
resolves10.1200/JCO.1998.16.8.2825
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
resolves10.3233/HAB-2004-13301
In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody
resolves10.1097/00007890-200201150-00019
TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE WITH RITUXIMAB
resolves10.1093/rheumatology/40.2.205
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
resolves10.1136/ard.61.10.883
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
resolves10.1111/j.1600-6143.2004.00502.x
Rituximab, Anti-CD20, Induces In Vivo Cytokine Release But Does Not Impair Ex Vivo T-Cell Responses
resolves10.1111/j.1399-0012.1992.tb00615.x
OKT3 treatment of acute renal allograft rejection in children
resolves10.1056/NEJM200109273451315
Fatal Reactivation of Cytomegalovirus Infection after Use of Rituximab for a Post-Transplantation Lymphoproliferative Disorder
resolves10.1093/ndt/gfh469
Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis
resolves10.1182/blood.V100.6.2257
Rituximab treatment results in impaired secondary humoral immune responsiveness
resolves10.1006/clim.2000.4980
Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)
resolves10.1111/j.1600-6143.2003.00646.x
Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174
resolves10.1385/MO:21:3:273
Posttransplant Lymphoma A Single-Center Experience of 500 Liver Transplantations
resolves10.1517/14728214.7.2.289
Rituximab and other emerging monoclonal antibody therapies for lymphoma
resolves10.1097/00007890-200108150-00010
REVERSAL OF STEROID- AND ANTI-LYMPHOCYTE ANTIBODY- RESISTANT REJECTION USING INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN RENAL TRANSPLANT RECIPIENTS
resolves10.1038/nm836
F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins
resolves10.1016/S0952-7915(98)80162-3
Long-lived plasma cells: a mechanism for maintaining persistent antibody production
resolves10.1126/science.1076071
Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells
resolves10.1093/intimm/13.12.1583
Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations
resolves10.1056/NEJMoa035588
Molecular Heterogeneity in Acute Renal Allograft Rejection Identified by DNA Microarray Profiling
resolves10.1111/j.1600-6143.2005.01009.x
Association of CD20+ Infiltrates with Poorer Clinical Outcomes in Acute Cellular Rejection of Renal Allografts
resolves10.1111/j.1399-0012.2004.00292.x
Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab
resolves10.1097/01.cji.0000155050.03916.04
Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis
resolves10.1517/14712598.5.1.S61
Molecules involved in T–B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity
resolves10.1093/annonc/11.suppl_1.S113
Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
resolves10.1080/08880010390203125
Anti-CD20 Monoclonal Antibody (Rituximab) for Therapy of Mediastinal CD20-Positive Large B-Cell Non-Hodgkin Lymphoma with a Local Tumor Extension into the Lung of a 10-Year-Old Girl
resolves10.1034/j.1399-3046.2003.00024.x
Treatment of monomorphic B‐cell lymphoma with rituximab after liver transplantation in a child
resolves10.1016/S1053-2498(02)00439-4
Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation
resolves10.1097/00007890-200210150-00018
Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients
resolves10.1016/S1053-2498(00)00326-0
Treatment of post-transplant lymphoproliferative disorder with monoclonal cd20 antibody (rituximab) after heart transplantation
resolves10.1046/j.1397-3142.2003.00135.x
The use of rituximab, anti‐CD20 monoclonal antibody, in pediatric transplantation
resolves10.1111/j.1600-6143.2005.01098.x
Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD)
resolves10.1016/j.transproceed.2004.12.114
New Strategy for ABO-Incompatible Living Donor Liver Transplantation With Anti-CD20 Antibody (Rituximab) and Plasma Exchange
resolves10.1111/j.1600-6143.2004.00507.x
Plasmapheresis, CMV Hyperimmune Globulin, and Anti-CD20 Allow ABO-Incompatible Renal Transplantation Without Splenectomy
resolves10.1111/j.1399-0012.2004.00151.x
Preconditioning regimen consisting of anti‐CD20 monoclonal antibody infusions, splenectomy and DFPP‐enabled non‐responders to undergo ABO‐incompatible kidney transplantation
resolves10.1111/j.1600-6143.2004.00653.x
ABO Incompatible Kidney Transplantations Without Splenectomy, Using Antigen-Specific Immunoadsorption and Rituximab
resolves10.1097/01.TP.0000149337.40911.E4
Successful Use of Anti-CD20 Monoclonal Antibody (Rituximab) for ABO-Incompatible Living-Related Liver Transplantation
resolves10.1111/j.1600-6143.2005.01031.x
ABO Incompatible High‐Titer Renal Transplantation without Splenectomy or Anti‐CD20 Treatment
resolves10.1097/00007890-200203270-00013
Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report
resolves10.1111/j.1600-6143.2004.00454.x
Rituximab as Treatment for Refractory Kidney Transplant Rejection
resolves10.1007/s00467-005-2013-7
Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome
The 23 references without a DOI — listed, not checked
no DOI — not checkedInterferon-g induces CD20 expression on multiple myeloma cells via induction of Pu.1 and augments rituximab binding to myeloma cells.
no DOI — not checkedPrimary analysis of a double-blind, placebo-controlled, dose-ranging trial of rituximab, an anti-CD20 monoclonal antibody, in patients with rheumatoid arthritis receiving methotrexate (DANCER TRIAL).
no DOI — not checkedThe anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin’s lymphoma (NHL) cell lines.
no DOI — not checkedEffective B-cell depletion in peripheral blood and tissue by single-dose rituximab in kidney transplant recipients: A pilot study.
no DOI — not checkedImmunomodulatory impact of rituximab and thymoglobuin therapy in liver transplantation.
no DOI — not checkedPost-transplant lymphoproliferative disorders (PTLD) in kidney transplantation: Report of 220 cases of a French registry.
no DOI — not checkedMeasurement of HLA antibody specificity by single antigen beads and MESF quatitation demonstrates efficacy of rituximab desensitization.
no DOI — not checkedCD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
no DOI — not checkedAnti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
no DOI — not checkedAnti-CD20 monoclonal antibody (rituximab) for pediatric post-transplant lymphoproliferative disorders: A preliminary multicenter experience.
no DOI — not checkedCD20 ligation using rituximab (anti-CD20 monoclonal antibody) inhibits growth of EBV infected B cells from a patient with PTLD.
no DOI — not checkedAnti-CD20 monoclonal antibody (rituximab) for post-transplant lymphoproliferative disease treatment (PTLD).
no DOI — not checkedAnti-CD20 antibody rituximab administration in patients with late-occurring lymphomas after solid organ transplant.
no DOI — not checkedRituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: A prospective trial in adults and children.
no DOI — not checkedLymphocyte subsets may discern treatment effects in children with post-transplant lymphoproliferative disorder (PTLD).
no DOI — not checkedThymoglobulin (T) in the management of steroid resistant acute cellular rejection (SRACR) in children.
no DOI — not checkedChoquet S Leblond V Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: Results of a prospective multicentre phase II study. Blood 2005.
no DOI — not checkedSuccessful ABO-incompatible kidney transplantation for non-responders with the use of anti-CD20 monoclonal antibody and plasmapheresis.
no DOI — not checkedSuccessful kidney transplant in ABO incompatible patients after plasmapheresis and thymoglobulin under a steroid avoidance protocol.
no DOI — not checkedLiving donor kidney transplantation in positive crossmatch patients.
no DOI — not checkedEarly allograft outcomes in patients with antibody mediated rejection treated with rituximab.
no DOI — not checkedRituximab rescue for refractory antibody mediated rejection after kidney transplantation.
no DOI — not checkedAchieving desensitization and preventing humoral rejection in positive crossmatch living donor kidney transplantation.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1111/j.1600-6143.2006.01288.x"><img src="https://citestamp.com/citestamped/10.1111/j.1600-6143.2006.01288.x/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1111/j.1600-6143.2006.01288.x)